nodes	percent_of_prediction	percent_of_DWPC	metapath
Dorzolamide—CA14—prostate gland—urinary bladder cancer	0.0126	0.0689	CbGeAlD
Dorzolamide—CA5A—female reproductive system—urinary bladder cancer	0.0124	0.0679	CbGeAlD
Dorzolamide—CYP2C9—urine—urinary bladder cancer	0.0119	0.065	CbGeAlD
Dorzolamide—CA14—seminal vesicle—urinary bladder cancer	0.0107	0.0583	CbGeAlD
Dorzolamide—CA7—renal system—urinary bladder cancer	0.0103	0.0564	CbGeAlD
Dorzolamide—CYP3A4—urine—urinary bladder cancer	0.00907	0.0496	CbGeAlD
Dorzolamide—CA5B—prostate gland—urinary bladder cancer	0.00882	0.0482	CbGeAlD
Dorzolamide—CA9—female reproductive system—urinary bladder cancer	0.00725	0.0396	CbGeAlD
Dorzolamide—CA12—renal system—urinary bladder cancer	0.0067	0.0366	CbGeAlD
Dorzolamide—CA4—prostate gland—urinary bladder cancer	0.00609	0.0333	CbGeAlD
Dorzolamide—CA5B—urethra—urinary bladder cancer	0.0059	0.0323	CbGeAlD
Dorzolamide—CA12—female reproductive system—urinary bladder cancer	0.00536	0.0293	CbGeAlD
Dorzolamide—CA1—renal system—urinary bladder cancer	0.00531	0.029	CbGeAlD
Dorzolamide—CA4—seminal vesicle—urinary bladder cancer	0.00515	0.0281	CbGeAlD
Dorzolamide—CA2—prostate gland—urinary bladder cancer	0.00505	0.0276	CbGeAlD
Dorzolamide—CA5B—female reproductive system—urinary bladder cancer	0.00481	0.0263	CbGeAlD
Dorzolamide—CA5B—vagina—urinary bladder cancer	0.00435	0.0238	CbGeAlD
Dorzolamide—CA2—seminal vesicle—urinary bladder cancer	0.00427	0.0233	CbGeAlD
Dorzolamide—CA1—female reproductive system—urinary bladder cancer	0.00425	0.0232	CbGeAlD
Dorzolamide—CA4—renal system—urinary bladder cancer	0.00415	0.0227	CbGeAlD
Dorzolamide—CA4—urethra—urinary bladder cancer	0.00407	0.0223	CbGeAlD
Dorzolamide—CA2—epithelium—urinary bladder cancer	0.00371	0.0203	CbGeAlD
Dorzolamide—CA2—smooth muscle tissue—urinary bladder cancer	0.00357	0.0195	CbGeAlD
Dorzolamide—CA2—renal system—urinary bladder cancer	0.00344	0.0188	CbGeAlD
Dorzolamide—CA4—female reproductive system—urinary bladder cancer	0.00332	0.0182	CbGeAlD
Dorzolamide—CA5B—lymph node—urinary bladder cancer	0.00282	0.0154	CbGeAlD
Dorzolamide—CA2—female reproductive system—urinary bladder cancer	0.00275	0.0151	CbGeAlD
Dorzolamide—CA2—vagina—urinary bladder cancer	0.00249	0.0136	CbGeAlD
Dorzolamide—CA1—lymph node—urinary bladder cancer	0.00249	0.0136	CbGeAlD
Dorzolamide—CYP2C9—female reproductive system—urinary bladder cancer	0.00233	0.0127	CbGeAlD
Dorzolamide—CYP3A4—renal system—urinary bladder cancer	0.00222	0.0121	CbGeAlD
Dorzolamide—CA4—lymph node—urinary bladder cancer	0.00194	0.0106	CbGeAlD
Dorzolamide—CYP3A4—female reproductive system—urinary bladder cancer	0.00178	0.00971	CbGeAlD
Dorzolamide—CA2—lymph node—urinary bladder cancer	0.00161	0.00881	CbGeAlD
Dorzolamide—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.00071	0.00108	CcSEcCtD
Dorzolamide—Angina pectoris—Epirubicin—urinary bladder cancer	0.000707	0.00108	CcSEcCtD
Dorzolamide—Anorexia—Etoposide—urinary bladder cancer	0.000702	0.00107	CcSEcCtD
Dorzolamide—Diarrhoea—Thiotepa—urinary bladder cancer	0.000701	0.00107	CcSEcCtD
Dorzolamide—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	0.000699	0.00107	CcSEcCtD
Dorzolamide—Decreased appetite—Cisplatin—urinary bladder cancer	0.000698	0.00107	CcSEcCtD
Dorzolamide—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000698	0.00107	CcSEcCtD
Dorzolamide—Bronchitis—Epirubicin—urinary bladder cancer	0.000698	0.00106	CcSEcCtD
Dorzolamide—Depression—Methotrexate—urinary bladder cancer	0.000689	0.00105	CcSEcCtD
Dorzolamide—Hypotension—Etoposide—urinary bladder cancer	0.000688	0.00105	CcSEcCtD
Dorzolamide—Pain—Cisplatin—urinary bladder cancer	0.000687	0.00105	CcSEcCtD
Dorzolamide—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.000685	0.00105	CcSEcCtD
Dorzolamide—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000681	0.00104	CcSEcCtD
Dorzolamide—Dysuria—Epirubicin—urinary bladder cancer	0.000678	0.00104	CcSEcCtD
Dorzolamide—Dizziness—Thiotepa—urinary bladder cancer	0.000678	0.00103	CcSEcCtD
Dorzolamide—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000674	0.00103	CcSEcCtD
Dorzolamide—Urticaria—Fluorouracil—urinary bladder cancer	0.000673	0.00103	CcSEcCtD
Dorzolamide—Conjunctivitis—Methotrexate—urinary bladder cancer	0.000672	0.00103	CcSEcCtD
Dorzolamide—Influenza—Doxorubicin—urinary bladder cancer	0.000671	0.00102	CcSEcCtD
Dorzolamide—Body temperature increased—Fluorouracil—urinary bladder cancer	0.00067	0.00102	CcSEcCtD
Dorzolamide—Sweating—Methotrexate—urinary bladder cancer	0.000663	0.00101	CcSEcCtD
Dorzolamide—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000662	0.00101	CcSEcCtD
Dorzolamide—Paraesthesia—Etoposide—urinary bladder cancer	0.000661	0.00101	CcSEcCtD
Dorzolamide—Weight decreased—Epirubicin—urinary bladder cancer	0.000656	0.001	CcSEcCtD
Dorzolamide—Dyspnoea—Etoposide—urinary bladder cancer	0.000656	0.001	CcSEcCtD
Dorzolamide—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000654	0.000999	CcSEcCtD
Dorzolamide—Somnolence—Etoposide—urinary bladder cancer	0.000654	0.000999	CcSEcCtD
Dorzolamide—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000654	0.000998	CcSEcCtD
Dorzolamide—Epistaxis—Methotrexate—urinary bladder cancer	0.000652	0.000995	CcSEcCtD
Dorzolamide—Vomiting—Thiotepa—urinary bladder cancer	0.000651	0.000994	CcSEcCtD
Dorzolamide—Rash—Thiotepa—urinary bladder cancer	0.000646	0.000986	CcSEcCtD
Dorzolamide—Bronchitis—Doxorubicin—urinary bladder cancer	0.000646	0.000985	CcSEcCtD
Dorzolamide—Dermatitis—Thiotepa—urinary bladder cancer	0.000645	0.000985	CcSEcCtD
Dorzolamide—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000645	0.000985	CcSEcCtD
Dorzolamide—Headache—Thiotepa—urinary bladder cancer	0.000642	0.00098	CcSEcCtD
Dorzolamide—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.000641	0.000979	CcSEcCtD
Dorzolamide—Decreased appetite—Etoposide—urinary bladder cancer	0.00064	0.000977	CcSEcCtD
Dorzolamide—Body temperature increased—Cisplatin—urinary bladder cancer	0.000635	0.000969	CcSEcCtD
Dorzolamide—Fatigue—Etoposide—urinary bladder cancer	0.000635	0.000969	CcSEcCtD
Dorzolamide—Pain—Etoposide—urinary bladder cancer	0.000629	0.000961	CcSEcCtD
Dorzolamide—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000629	0.00096	CcSEcCtD
Dorzolamide—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000629	0.00096	CcSEcCtD
Dorzolamide—Dysuria—Doxorubicin—urinary bladder cancer	0.000628	0.000958	CcSEcCtD
Dorzolamide—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000624	0.000953	CcSEcCtD
Dorzolamide—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000624	0.000952	CcSEcCtD
Dorzolamide—Sweating—Epirubicin—urinary bladder cancer	0.00062	0.000947	CcSEcCtD
Dorzolamide—Asthenia—Gemcitabine—urinary bladder cancer	0.000618	0.000944	CcSEcCtD
Dorzolamide—Pharyngitis—Methotrexate—urinary bladder cancer	0.000616	0.00094	CcSEcCtD
Dorzolamide—Epistaxis—Epirubicin—urinary bladder cancer	0.00061	0.000931	CcSEcCtD
Dorzolamide—Pruritus—Gemcitabine—urinary bladder cancer	0.00061	0.000931	CcSEcCtD
Dorzolamide—Nausea—Thiotepa—urinary bladder cancer	0.000609	0.000929	CcSEcCtD
Dorzolamide—Weight decreased—Doxorubicin—urinary bladder cancer	0.000607	0.000927	CcSEcCtD
Dorzolamide—Sinusitis—Epirubicin—urinary bladder cancer	0.000607	0.000926	CcSEcCtD
Dorzolamide—Feeling abnormal—Etoposide—urinary bladder cancer	0.000606	0.000926	CcSEcCtD
Dorzolamide—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000605	0.000924	CcSEcCtD
Dorzolamide—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000604	0.000921	CcSEcCtD
Dorzolamide—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000602	0.000919	CcSEcCtD
Dorzolamide—Pruritus—Fluorouracil—urinary bladder cancer	0.0006	0.000915	CcSEcCtD
Dorzolamide—Visual impairment—Methotrexate—urinary bladder cancer	0.000598	0.000913	CcSEcCtD
Dorzolamide—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000593	0.000906	CcSEcCtD
Dorzolamide—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000592	0.000903	CcSEcCtD
Dorzolamide—Bradycardia—Epirubicin—urinary bladder cancer	0.000591	0.000902	CcSEcCtD
Dorzolamide—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00059	0.0009	CcSEcCtD
Dorzolamide—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000587	0.000896	CcSEcCtD
Dorzolamide—Urticaria—Etoposide—urinary bladder cancer	0.000585	0.000892	CcSEcCtD
Dorzolamide—Abdominal pain—Etoposide—urinary bladder cancer	0.000582	0.000888	CcSEcCtD
Dorzolamide—Body temperature increased—Etoposide—urinary bladder cancer	0.000582	0.000888	CcSEcCtD
Dorzolamide—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000582	0.000888	CcSEcCtD
Dorzolamide—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000582	0.000888	CcSEcCtD
Dorzolamide—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00058	0.000885	CcSEcCtD
Dorzolamide—Tinnitus—Methotrexate—urinary bladder cancer	0.000579	0.000883	CcSEcCtD
Dorzolamide—Asthenia—Cisplatin—urinary bladder cancer	0.000576	0.00088	CcSEcCtD
Dorzolamide—Pharyngitis—Epirubicin—urinary bladder cancer	0.000576	0.00088	CcSEcCtD
Dorzolamide—Sweating—Doxorubicin—urinary bladder cancer	0.000574	0.000876	CcSEcCtD
Dorzolamide—Epistaxis—Doxorubicin—urinary bladder cancer	0.000565	0.000862	CcSEcCtD
Dorzolamide—Sinusitis—Doxorubicin—urinary bladder cancer	0.000561	0.000857	CcSEcCtD
Dorzolamide—Dizziness—Fluorouracil—urinary bladder cancer	0.00056	0.000855	CcSEcCtD
Dorzolamide—Visual impairment—Epirubicin—urinary bladder cancer	0.00056	0.000854	CcSEcCtD
Dorzolamide—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000559	0.000853	CcSEcCtD
Dorzolamide—Diarrhoea—Cisplatin—urinary bladder cancer	0.00055	0.000839	CcSEcCtD
Dorzolamide—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000549	0.000838	CcSEcCtD
Dorzolamide—Alopecia—Methotrexate—urinary bladder cancer	0.000548	0.000837	CcSEcCtD
Dorzolamide—Vomiting—Gemcitabine—urinary bladder cancer	0.000548	0.000836	CcSEcCtD
Dorzolamide—Bradycardia—Doxorubicin—urinary bladder cancer	0.000547	0.000835	CcSEcCtD
Dorzolamide—Rash—Gemcitabine—urinary bladder cancer	0.000543	0.00083	CcSEcCtD
Dorzolamide—Dermatitis—Gemcitabine—urinary bladder cancer	0.000543	0.000829	CcSEcCtD
Dorzolamide—Hypersensitivity—Etoposide—urinary bladder cancer	0.000542	0.000828	CcSEcCtD
Dorzolamide—Tinnitus—Epirubicin—urinary bladder cancer	0.000541	0.000826	CcSEcCtD
Dorzolamide—Erythema—Methotrexate—urinary bladder cancer	0.00054	0.000824	CcSEcCtD
Dorzolamide—Headache—Gemcitabine—urinary bladder cancer	0.00054	0.000824	CcSEcCtD
Dorzolamide—Vomiting—Fluorouracil—urinary bladder cancer	0.000539	0.000822	CcSEcCtD
Dorzolamide—Rash—Fluorouracil—urinary bladder cancer	0.000534	0.000816	CcSEcCtD
Dorzolamide—Dermatitis—Fluorouracil—urinary bladder cancer	0.000534	0.000815	CcSEcCtD
Dorzolamide—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000533	0.000814	CcSEcCtD
Dorzolamide—Headache—Fluorouracil—urinary bladder cancer	0.000531	0.00081	CcSEcCtD
Dorzolamide—Dysgeusia—Methotrexate—urinary bladder cancer	0.000529	0.000807	CcSEcCtD
Dorzolamide—Asthenia—Etoposide—urinary bladder cancer	0.000528	0.000806	CcSEcCtD
Dorzolamide—Back pain—Methotrexate—urinary bladder cancer	0.000522	0.000798	CcSEcCtD
Dorzolamide—Pruritus—Etoposide—urinary bladder cancer	0.000521	0.000795	CcSEcCtD
Dorzolamide—Arrhythmia—Epirubicin—urinary bladder cancer	0.000519	0.000792	CcSEcCtD
Dorzolamide—Visual impairment—Doxorubicin—urinary bladder cancer	0.000518	0.00079	CcSEcCtD
Dorzolamide—Alopecia—Epirubicin—urinary bladder cancer	0.000513	0.000783	CcSEcCtD
Dorzolamide—Nausea—Gemcitabine—urinary bladder cancer	0.000512	0.000781	CcSEcCtD
Dorzolamide—Vomiting—Cisplatin—urinary bladder cancer	0.000511	0.00078	CcSEcCtD
Dorzolamide—Vision blurred—Methotrexate—urinary bladder cancer	0.000509	0.000777	CcSEcCtD
Dorzolamide—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000508	0.000775	CcSEcCtD
Dorzolamide—Rash—Cisplatin—urinary bladder cancer	0.000507	0.000773	CcSEcCtD
Dorzolamide—Dermatitis—Cisplatin—urinary bladder cancer	0.000506	0.000772	CcSEcCtD
Dorzolamide—Erythema—Epirubicin—urinary bladder cancer	0.000505	0.000772	CcSEcCtD
Dorzolamide—Diarrhoea—Etoposide—urinary bladder cancer	0.000504	0.000769	CcSEcCtD
Dorzolamide—Nausea—Fluorouracil—urinary bladder cancer	0.000503	0.000768	CcSEcCtD
Dorzolamide—Tinnitus—Doxorubicin—urinary bladder cancer	0.000501	0.000765	CcSEcCtD
Dorzolamide—Tension—Epirubicin—urinary bladder cancer	0.000496	0.000757	CcSEcCtD
Dorzolamide—Dysgeusia—Epirubicin—urinary bladder cancer	0.000495	0.000756	CcSEcCtD
Dorzolamide—Nervousness—Epirubicin—urinary bladder cancer	0.000491	0.000749	CcSEcCtD
Dorzolamide—Back pain—Epirubicin—urinary bladder cancer	0.000489	0.000746	CcSEcCtD
Dorzolamide—Dizziness—Etoposide—urinary bladder cancer	0.000487	0.000743	CcSEcCtD
Dorzolamide—Vertigo—Methotrexate—urinary bladder cancer	0.000485	0.000741	CcSEcCtD
Dorzolamide—Arrhythmia—Doxorubicin—urinary bladder cancer	0.00048	0.000733	CcSEcCtD
Dorzolamide—Nausea—Cisplatin—urinary bladder cancer	0.000477	0.000728	CcSEcCtD
Dorzolamide—Vision blurred—Epirubicin—urinary bladder cancer	0.000476	0.000727	CcSEcCtD
Dorzolamide—Alopecia—Doxorubicin—urinary bladder cancer	0.000475	0.000725	CcSEcCtD
Dorzolamide—Cough—Methotrexate—urinary bladder cancer	0.000471	0.000719	CcSEcCtD
Dorzolamide—Vomiting—Etoposide—urinary bladder cancer	0.000468	0.000714	CcSEcCtD
Dorzolamide—Erythema—Doxorubicin—urinary bladder cancer	0.000468	0.000714	CcSEcCtD
Dorzolamide—Rash—Etoposide—urinary bladder cancer	0.000464	0.000708	CcSEcCtD
Dorzolamide—Dermatitis—Etoposide—urinary bladder cancer	0.000464	0.000708	CcSEcCtD
Dorzolamide—Headache—Etoposide—urinary bladder cancer	0.000461	0.000704	CcSEcCtD
Dorzolamide—Arthralgia—Methotrexate—urinary bladder cancer	0.00046	0.000702	CcSEcCtD
Dorzolamide—Chest pain—Methotrexate—urinary bladder cancer	0.00046	0.000702	CcSEcCtD
Dorzolamide—Tension—Doxorubicin—urinary bladder cancer	0.000459	0.000701	CcSEcCtD
Dorzolamide—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000458	0.000699	CcSEcCtD
Dorzolamide—Discomfort—Methotrexate—urinary bladder cancer	0.000454	0.000694	CcSEcCtD
Dorzolamide—Nervousness—Doxorubicin—urinary bladder cancer	0.000454	0.000693	CcSEcCtD
Dorzolamide—Vertigo—Epirubicin—urinary bladder cancer	0.000454	0.000693	CcSEcCtD
Dorzolamide—Syncope—Epirubicin—urinary bladder cancer	0.000453	0.000692	CcSEcCtD
Dorzolamide—Back pain—Doxorubicin—urinary bladder cancer	0.000452	0.000691	CcSEcCtD
Dorzolamide—Palpitations—Epirubicin—urinary bladder cancer	0.000447	0.000682	CcSEcCtD
Dorzolamide—Confusional state—Methotrexate—urinary bladder cancer	0.000444	0.000678	CcSEcCtD
Dorzolamide—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000444	0.000678	CcSEcCtD
Dorzolamide—Cough—Epirubicin—urinary bladder cancer	0.000441	0.000673	CcSEcCtD
Dorzolamide—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000441	0.000673	CcSEcCtD
Dorzolamide—Vision blurred—Doxorubicin—urinary bladder cancer	0.000441	0.000673	CcSEcCtD
Dorzolamide—Nausea—Etoposide—urinary bladder cancer	0.000437	0.000667	CcSEcCtD
Dorzolamide—Hypertension—Epirubicin—urinary bladder cancer	0.000436	0.000666	CcSEcCtD
Dorzolamide—Chest pain—Epirubicin—urinary bladder cancer	0.00043	0.000657	CcSEcCtD
Dorzolamide—Arthralgia—Epirubicin—urinary bladder cancer	0.00043	0.000657	CcSEcCtD
Dorzolamide—Anxiety—Epirubicin—urinary bladder cancer	0.000429	0.000655	CcSEcCtD
Dorzolamide—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000426	0.000651	CcSEcCtD
Dorzolamide—Discomfort—Epirubicin—urinary bladder cancer	0.000425	0.000649	CcSEcCtD
Dorzolamide—Dry mouth—Epirubicin—urinary bladder cancer	0.000421	0.000642	CcSEcCtD
Dorzolamide—Vertigo—Doxorubicin—urinary bladder cancer	0.00042	0.000641	CcSEcCtD
Dorzolamide—Anorexia—Methotrexate—urinary bladder cancer	0.00042	0.000641	CcSEcCtD
Dorzolamide—Syncope—Doxorubicin—urinary bladder cancer	0.000419	0.00064	CcSEcCtD
Dorzolamide—Confusional state—Epirubicin—urinary bladder cancer	0.000416	0.000635	CcSEcCtD
Dorzolamide—Palpitations—Doxorubicin—urinary bladder cancer	0.000413	0.000631	CcSEcCtD
Dorzolamide—Oedema—Epirubicin—urinary bladder cancer	0.000413	0.00063	CcSEcCtD
Dorzolamide—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000413	0.00063	CcSEcCtD
Dorzolamide—Hypotension—Methotrexate—urinary bladder cancer	0.000412	0.000629	CcSEcCtD
Dorzolamide—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000411	0.000627	CcSEcCtD
Dorzolamide—Cough—Doxorubicin—urinary bladder cancer	0.000408	0.000623	CcSEcCtD
Dorzolamide—Shock—Epirubicin—urinary bladder cancer	0.000406	0.00062	CcSEcCtD
Dorzolamide—Hypertension—Doxorubicin—urinary bladder cancer	0.000404	0.000616	CcSEcCtD
Dorzolamide—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000402	0.000613	CcSEcCtD
Dorzolamide—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000399	0.000609	CcSEcCtD
Dorzolamide—Insomnia—Methotrexate—urinary bladder cancer	0.000399	0.000609	CcSEcCtD
Dorzolamide—Arthralgia—Doxorubicin—urinary bladder cancer	0.000398	0.000608	CcSEcCtD
Dorzolamide—Chest pain—Doxorubicin—urinary bladder cancer	0.000398	0.000608	CcSEcCtD
Dorzolamide—Anxiety—Doxorubicin—urinary bladder cancer	0.000397	0.000606	CcSEcCtD
Dorzolamide—Paraesthesia—Methotrexate—urinary bladder cancer	0.000396	0.000604	CcSEcCtD
Dorzolamide—Discomfort—Doxorubicin—urinary bladder cancer	0.000393	0.000601	CcSEcCtD
Dorzolamide—Anorexia—Epirubicin—urinary bladder cancer	0.000393	0.0006	CcSEcCtD
Dorzolamide—Dyspnoea—Methotrexate—urinary bladder cancer	0.000393	0.0006	CcSEcCtD
Dorzolamide—Somnolence—Methotrexate—urinary bladder cancer	0.000392	0.000598	CcSEcCtD
Dorzolamide—Dry mouth—Doxorubicin—urinary bladder cancer	0.000389	0.000594	CcSEcCtD
Dorzolamide—Dyspepsia—Methotrexate—urinary bladder cancer	0.000388	0.000592	CcSEcCtD
Dorzolamide—Hypotension—Epirubicin—urinary bladder cancer	0.000385	0.000588	CcSEcCtD
Dorzolamide—Confusional state—Doxorubicin—urinary bladder cancer	0.000385	0.000588	CcSEcCtD
Dorzolamide—Decreased appetite—Methotrexate—urinary bladder cancer	0.000383	0.000585	CcSEcCtD
Dorzolamide—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000382	0.000583	CcSEcCtD
Dorzolamide—Oedema—Doxorubicin—urinary bladder cancer	0.000382	0.000583	CcSEcCtD
Dorzolamide—Fatigue—Methotrexate—urinary bladder cancer	0.00038	0.00058	CcSEcCtD
Dorzolamide—Pain—Methotrexate—urinary bladder cancer	0.000377	0.000575	CcSEcCtD
Dorzolamide—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000376	0.000574	CcSEcCtD
Dorzolamide—Shock—Doxorubicin—urinary bladder cancer	0.000376	0.000573	CcSEcCtD
Dorzolamide—Insomnia—Epirubicin—urinary bladder cancer	0.000373	0.00057	CcSEcCtD
Dorzolamide—Paraesthesia—Epirubicin—urinary bladder cancer	0.00037	0.000565	CcSEcCtD
Dorzolamide—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000369	0.000563	CcSEcCtD
Dorzolamide—Dyspnoea—Epirubicin—urinary bladder cancer	0.000368	0.000561	CcSEcCtD
Dorzolamide—Somnolence—Epirubicin—urinary bladder cancer	0.000367	0.00056	CcSEcCtD
Dorzolamide—Anorexia—Doxorubicin—urinary bladder cancer	0.000364	0.000555	CcSEcCtD
Dorzolamide—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000363	0.000555	CcSEcCtD
Dorzolamide—Dyspepsia—Epirubicin—urinary bladder cancer	0.000363	0.000554	CcSEcCtD
Dorzolamide—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.00036	0.00055	CcSEcCtD
Dorzolamide—Decreased appetite—Epirubicin—urinary bladder cancer	0.000359	0.000547	CcSEcCtD
Dorzolamide—Hypotension—Doxorubicin—urinary bladder cancer	0.000357	0.000544	CcSEcCtD
Dorzolamide—Fatigue—Epirubicin—urinary bladder cancer	0.000356	0.000543	CcSEcCtD
Dorzolamide—Pain—Epirubicin—urinary bladder cancer	0.000353	0.000539	CcSEcCtD
Dorzolamide—Urticaria—Methotrexate—urinary bladder cancer	0.00035	0.000535	CcSEcCtD
Dorzolamide—Body temperature increased—Methotrexate—urinary bladder cancer	0.000348	0.000532	CcSEcCtD
Dorzolamide—Abdominal pain—Methotrexate—urinary bladder cancer	0.000348	0.000532	CcSEcCtD
Dorzolamide—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000348	0.000531	CcSEcCtD
Dorzolamide—Insomnia—Doxorubicin—urinary bladder cancer	0.000345	0.000527	CcSEcCtD
Dorzolamide—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000343	0.000523	CcSEcCtD
Dorzolamide—Dyspnoea—Doxorubicin—urinary bladder cancer	0.00034	0.000519	CcSEcCtD
Dorzolamide—Feeling abnormal—Epirubicin—urinary bladder cancer	0.00034	0.000519	CcSEcCtD
Dorzolamide—Somnolence—Doxorubicin—urinary bladder cancer	0.000339	0.000518	CcSEcCtD
Dorzolamide—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000337	0.000515	CcSEcCtD
Dorzolamide—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000336	0.000513	CcSEcCtD
Dorzolamide—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000332	0.000507	CcSEcCtD
Dorzolamide—Fatigue—Doxorubicin—urinary bladder cancer	0.000329	0.000502	CcSEcCtD
Dorzolamide—Urticaria—Epirubicin—urinary bladder cancer	0.000328	0.0005	CcSEcCtD
Dorzolamide—Pain—Doxorubicin—urinary bladder cancer	0.000326	0.000498	CcSEcCtD
Dorzolamide—Body temperature increased—Epirubicin—urinary bladder cancer	0.000326	0.000498	CcSEcCtD
Dorzolamide—Abdominal pain—Epirubicin—urinary bladder cancer	0.000326	0.000498	CcSEcCtD
Dorzolamide—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000325	0.000496	CcSEcCtD
Dorzolamide—Asthenia—Methotrexate—urinary bladder cancer	0.000316	0.000483	CcSEcCtD
Dorzolamide—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000315	0.00048	CcSEcCtD
Dorzolamide—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000312	0.000476	CcSEcCtD
Dorzolamide—Pruritus—Methotrexate—urinary bladder cancer	0.000312	0.000476	CcSEcCtD
Dorzolamide—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000304	0.000464	CcSEcCtD
Dorzolamide—Urticaria—Doxorubicin—urinary bladder cancer	0.000303	0.000463	CcSEcCtD
Dorzolamide—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000302	0.000461	CcSEcCtD
Dorzolamide—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000302	0.000461	CcSEcCtD
Dorzolamide—Diarrhoea—Methotrexate—urinary bladder cancer	0.000302	0.00046	CcSEcCtD
Dorzolamide—Asthenia—Epirubicin—urinary bladder cancer	0.000296	0.000452	CcSEcCtD
Dorzolamide—Pruritus—Epirubicin—urinary bladder cancer	0.000292	0.000446	CcSEcCtD
Dorzolamide—Dizziness—Methotrexate—urinary bladder cancer	0.000292	0.000445	CcSEcCtD
Dorzolamide—CA9—Cellular responses to stress—RB1—urinary bladder cancer	0.000289	0.00178	CbGpPWpGaD
Dorzolamide—CA6—Metabolism—GSTT1—urinary bladder cancer	0.000286	0.00177	CbGpPWpGaD
Dorzolamide—CA5A—Metabolism—GSTT1—urinary bladder cancer	0.000286	0.00177	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—PRSS3—urinary bladder cancer	0.000284	0.00176	CbGpPWpGaD
Dorzolamide—Diarrhoea—Epirubicin—urinary bladder cancer	0.000282	0.000431	CcSEcCtD
Dorzolamide—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000281	0.000429	CcSEcCtD
Dorzolamide—CA4—Metabolism—TYMP—urinary bladder cancer	0.000281	0.00174	CbGpPWpGaD
Dorzolamide—Vomiting—Methotrexate—urinary bladder cancer	0.00028	0.000428	CcSEcCtD
Dorzolamide—Rash—Methotrexate—urinary bladder cancer	0.000278	0.000424	CcSEcCtD
Dorzolamide—Dermatitis—Methotrexate—urinary bladder cancer	0.000278	0.000424	CcSEcCtD
Dorzolamide—Headache—Methotrexate—urinary bladder cancer	0.000276	0.000422	CcSEcCtD
Dorzolamide—CA12—Metabolism—RRM2—urinary bladder cancer	0.000275	0.0017	CbGpPWpGaD
Dorzolamide—CA7—Metabolism—ENO2—urinary bladder cancer	0.000275	0.0017	CbGpPWpGaD
Dorzolamide—CA5B—Metabolism—HPGDS—urinary bladder cancer	0.000275	0.0017	CbGpPWpGaD
Dorzolamide—CA7—Metabolism—HPGDS—urinary bladder cancer	0.000275	0.0017	CbGpPWpGaD
Dorzolamide—CA5B—Metabolism—ENO2—urinary bladder cancer	0.000275	0.0017	CbGpPWpGaD
Dorzolamide—Asthenia—Doxorubicin—urinary bladder cancer	0.000274	0.000418	CcSEcCtD
Dorzolamide—Dizziness—Epirubicin—urinary bladder cancer	0.000273	0.000416	CcSEcCtD
Dorzolamide—Pruritus—Doxorubicin—urinary bladder cancer	0.00027	0.000412	CcSEcCtD
Dorzolamide—CA2—Metabolism—TYMP—urinary bladder cancer	0.00027	0.00166	CbGpPWpGaD
Dorzolamide—CA7—Metabolism—GSTT1—urinary bladder cancer	0.000267	0.00165	CbGpPWpGaD
Dorzolamide—CA5B—Metabolism—GSTT1—urinary bladder cancer	0.000267	0.00165	CbGpPWpGaD
Dorzolamide—Vomiting—Epirubicin—urinary bladder cancer	0.000262	0.0004	CcSEcCtD
Dorzolamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000262	0.00162	CbGpPWpGaD
Dorzolamide—Nausea—Methotrexate—urinary bladder cancer	0.000262	0.0004	CcSEcCtD
Dorzolamide—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000261	0.000399	CcSEcCtD
Dorzolamide—Rash—Epirubicin—urinary bladder cancer	0.00026	0.000397	CcSEcCtD
Dorzolamide—Dermatitis—Epirubicin—urinary bladder cancer	0.00026	0.000397	CcSEcCtD
Dorzolamide—CA1—Metabolism—TYMP—urinary bladder cancer	0.000258	0.0016	CbGpPWpGaD
Dorzolamide—Headache—Epirubicin—urinary bladder cancer	0.000258	0.000394	CcSEcCtD
Dorzolamide—CA12—Metabolism—ENO2—urinary bladder cancer	0.000255	0.00157	CbGpPWpGaD
Dorzolamide—CA12—Metabolism—HPGDS—urinary bladder cancer	0.000255	0.00157	CbGpPWpGaD
Dorzolamide—CA4—Metabolism—NAT2—urinary bladder cancer	0.000254	0.00157	CbGpPWpGaD
Dorzolamide—CA9—Cellular responses to stress—CDKN2A—urinary bladder cancer	0.000254	0.00157	CbGpPWpGaD
Dorzolamide—Dizziness—Doxorubicin—urinary bladder cancer	0.000252	0.000385	CcSEcCtD
Dorzolamide—CA12—Metabolism—GSTT1—urinary bladder cancer	0.000247	0.00153	CbGpPWpGaD
Dorzolamide—CYP2C9—Biological oxidations—HPGDS—urinary bladder cancer	0.000245	0.00151	CbGpPWpGaD
Dorzolamide—Nausea—Epirubicin—urinary bladder cancer	0.000245	0.000374	CcSEcCtD
Dorzolamide—CA14—Metabolism—NQO1—urinary bladder cancer	0.000244	0.00151	CbGpPWpGaD
Dorzolamide—CA2—Metabolism—NAT2—urinary bladder cancer	0.000244	0.00151	CbGpPWpGaD
Dorzolamide—Vomiting—Doxorubicin—urinary bladder cancer	0.000243	0.00037	CcSEcCtD
Dorzolamide—Rash—Doxorubicin—urinary bladder cancer	0.000241	0.000367	CcSEcCtD
Dorzolamide—Dermatitis—Doxorubicin—urinary bladder cancer	0.00024	0.000367	CcSEcCtD
Dorzolamide—Headache—Doxorubicin—urinary bladder cancer	0.000239	0.000365	CcSEcCtD
Dorzolamide—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	0.000238	0.00147	CbGpPWpGaD
Dorzolamide—CA5A—Metabolism—NQO1—urinary bladder cancer	0.000238	0.00147	CbGpPWpGaD
Dorzolamide—CA6—Metabolism—NQO1—urinary bladder cancer	0.000238	0.00147	CbGpPWpGaD
Dorzolamide—CA1—Metabolism—NAT2—urinary bladder cancer	0.000234	0.00144	CbGpPWpGaD
Dorzolamide—CA9—Cellular responses to stress—CXCL8—urinary bladder cancer	0.00023	0.00142	CbGpPWpGaD
Dorzolamide—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000229	0.00142	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—TYMP—urinary bladder cancer	0.000227	0.0014	CbGpPWpGaD
Dorzolamide—Nausea—Doxorubicin—urinary bladder cancer	0.000227	0.000346	CcSEcCtD
Dorzolamide—CA5B—Metabolism—NQO1—urinary bladder cancer	0.000222	0.00137	CbGpPWpGaD
Dorzolamide—CA7—Metabolism—NQO1—urinary bladder cancer	0.000222	0.00137	CbGpPWpGaD
Dorzolamide—CA4—Metabolism—RRM2—urinary bladder cancer	0.00022	0.00136	CbGpPWpGaD
Dorzolamide—CA2—Metabolism—RRM2—urinary bladder cancer	0.00021	0.0013	CbGpPWpGaD
Dorzolamide—CA9—Cellular responses to stress—CDKN1A—urinary bladder cancer	0.000208	0.00128	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—NAT2—urinary bladder cancer	0.000206	0.00127	CbGpPWpGaD
Dorzolamide—CA12—Metabolism—NQO1—urinary bladder cancer	0.000206	0.00127	CbGpPWpGaD
Dorzolamide—CA14—Metabolism—GSTP1—urinary bladder cancer	0.000203	0.00126	CbGpPWpGaD
Dorzolamide—CA4—Metabolism—HPGDS—urinary bladder cancer	0.000203	0.00126	CbGpPWpGaD
Dorzolamide—CA4—Metabolism—ENO2—urinary bladder cancer	0.000203	0.00126	CbGpPWpGaD
Dorzolamide—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000202	0.00125	CbGpPWpGaD
Dorzolamide—CA1—Metabolism—RRM2—urinary bladder cancer	0.000202	0.00125	CbGpPWpGaD
Dorzolamide—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.0002	0.00123	CbGpPWpGaD
Dorzolamide—CA5A—Metabolism—GSTP1—urinary bladder cancer	0.000198	0.00122	CbGpPWpGaD
Dorzolamide—CA6—Metabolism—GSTP1—urinary bladder cancer	0.000198	0.00122	CbGpPWpGaD
Dorzolamide—CA9—Cellular responses to stress—EP300—urinary bladder cancer	0.000198	0.00122	CbGpPWpGaD
Dorzolamide—CA4—Metabolism—GSTT1—urinary bladder cancer	0.000197	0.00122	CbGpPWpGaD
Dorzolamide—CA2—Metabolism—ENO2—urinary bladder cancer	0.000195	0.0012	CbGpPWpGaD
Dorzolamide—CA2—Metabolism—HPGDS—urinary bladder cancer	0.000195	0.0012	CbGpPWpGaD
Dorzolamide—CA2—Metabolism—GSTT1—urinary bladder cancer	0.000189	0.00117	CbGpPWpGaD
Dorzolamide—CA14—Metabolism—TYMS—urinary bladder cancer	0.000189	0.00117	CbGpPWpGaD
Dorzolamide—CA1—Metabolism—ENO2—urinary bladder cancer	0.000187	0.00115	CbGpPWpGaD
Dorzolamide—CA1—Metabolism—HPGDS—urinary bladder cancer	0.000187	0.00115	CbGpPWpGaD
Dorzolamide—CA14—Metabolism—GSTM1—urinary bladder cancer	0.000187	0.00115	CbGpPWpGaD
Dorzolamide—CA14—Metabolism—NCOR1—urinary bladder cancer	0.000187	0.00115	CbGpPWpGaD
Dorzolamide—CA5B—Metabolism—GSTP1—urinary bladder cancer	0.000185	0.00114	CbGpPWpGaD
Dorzolamide—CA7—Metabolism—GSTP1—urinary bladder cancer	0.000185	0.00114	CbGpPWpGaD
Dorzolamide—CA6—Metabolism—TYMS—urinary bladder cancer	0.000184	0.00114	CbGpPWpGaD
Dorzolamide—CA5A—Metabolism—TYMS—urinary bladder cancer	0.000184	0.00114	CbGpPWpGaD
Dorzolamide—CA5A—Metabolism—GSTM1—urinary bladder cancer	0.000182	0.00112	CbGpPWpGaD
Dorzolamide—CA6—Metabolism—GSTM1—urinary bladder cancer	0.000182	0.00112	CbGpPWpGaD
Dorzolamide—CA6—Metabolism—NCOR1—urinary bladder cancer	0.000182	0.00112	CbGpPWpGaD
Dorzolamide—CA5A—Metabolism—NCOR1—urinary bladder cancer	0.000182	0.00112	CbGpPWpGaD
Dorzolamide—CA1—Metabolism—GSTT1—urinary bladder cancer	0.000181	0.00112	CbGpPWpGaD
Dorzolamide—CA14—Metabolism—GPX1—urinary bladder cancer	0.000179	0.00111	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—RRM2—urinary bladder cancer	0.000177	0.0011	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000177	0.00109	CbGpPWpGaD
Dorzolamide—CA14—Metabolism—ERCC2—urinary bladder cancer	0.000176	0.00108	CbGpPWpGaD
Dorzolamide—CA5A—Metabolism—GPX1—urinary bladder cancer	0.000174	0.00108	CbGpPWpGaD
Dorzolamide—CA6—Metabolism—GPX1—urinary bladder cancer	0.000174	0.00108	CbGpPWpGaD
Dorzolamide—CA7—Metabolism—TYMS—urinary bladder cancer	0.000172	0.00106	CbGpPWpGaD
Dorzolamide—CA5B—Metabolism—TYMS—urinary bladder cancer	0.000172	0.00106	CbGpPWpGaD
Dorzolamide—CA12—Metabolism—GSTP1—urinary bladder cancer	0.000171	0.00106	CbGpPWpGaD
Dorzolamide—CA6—Metabolism—ERCC2—urinary bladder cancer	0.000171	0.00106	CbGpPWpGaD
Dorzolamide—CA5A—Metabolism—ERCC2—urinary bladder cancer	0.000171	0.00106	CbGpPWpGaD
Dorzolamide—CA7—Metabolism—GSTM1—urinary bladder cancer	0.00017	0.00105	CbGpPWpGaD
Dorzolamide—CA5B—Metabolism—GSTM1—urinary bladder cancer	0.00017	0.00105	CbGpPWpGaD
Dorzolamide—CA7—Metabolism—NCOR1—urinary bladder cancer	0.00017	0.00105	CbGpPWpGaD
Dorzolamide—CA5B—Metabolism—NCOR1—urinary bladder cancer	0.00017	0.00105	CbGpPWpGaD
Dorzolamide—CA14—Metabolism—MTHFR—urinary bladder cancer	0.000165	0.00102	CbGpPWpGaD
Dorzolamide—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	0.000165	0.00102	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—ENO2—urinary bladder cancer	0.000164	0.00101	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—HPGDS—urinary bladder cancer	0.000164	0.00101	CbGpPWpGaD
Dorzolamide—CA4—Metabolism—NQO1—urinary bladder cancer	0.000164	0.00101	CbGpPWpGaD
Dorzolamide—CA7—Metabolism—GPX1—urinary bladder cancer	0.000163	0.00101	CbGpPWpGaD
Dorzolamide—CA5B—Metabolism—GPX1—urinary bladder cancer	0.000163	0.00101	CbGpPWpGaD
Dorzolamide—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000163	0.001	CbGpPWpGaD
Dorzolamide—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.000162	0.000999	CbGpPWpGaD
Dorzolamide—CA6—Metabolism—MTHFR—urinary bladder cancer	0.000161	0.000994	CbGpPWpGaD
Dorzolamide—CA5A—Metabolism—MTHFR—urinary bladder cancer	0.000161	0.000994	CbGpPWpGaD
Dorzolamide—CA5B—Metabolism—ERCC2—urinary bladder cancer	0.00016	0.000987	CbGpPWpGaD
Dorzolamide—CA7—Metabolism—ERCC2—urinary bladder cancer	0.00016	0.000987	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—GSTT1—urinary bladder cancer	0.000159	0.000984	CbGpPWpGaD
Dorzolamide—CA12—Metabolism—TYMS—urinary bladder cancer	0.000159	0.000984	CbGpPWpGaD
Dorzolamide—CA12—Metabolism—NCOR1—urinary bladder cancer	0.000158	0.000973	CbGpPWpGaD
Dorzolamide—CA12—Metabolism—GSTM1—urinary bladder cancer	0.000158	0.000973	CbGpPWpGaD
Dorzolamide—CA2—Metabolism—NQO1—urinary bladder cancer	0.000157	0.00097	CbGpPWpGaD
Dorzolamide—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.000157	0.000969	CbGpPWpGaD
Dorzolamide—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	0.000151	0.000935	CbGpPWpGaD
Dorzolamide—CA12—Metabolism—GPX1—urinary bladder cancer	0.000151	0.000931	CbGpPWpGaD
Dorzolamide—CA1—Metabolism—NQO1—urinary bladder cancer	0.000151	0.00093	CbGpPWpGaD
Dorzolamide—CA5B—Metabolism—MTHFR—urinary bladder cancer	0.00015	0.000928	CbGpPWpGaD
Dorzolamide—CA7—Metabolism—MTHFR—urinary bladder cancer	0.00015	0.000928	CbGpPWpGaD
Dorzolamide—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000149	0.000923	CbGpPWpGaD
Dorzolamide—CA12—Metabolism—ERCC2—urinary bladder cancer	0.000148	0.000914	CbGpPWpGaD
Dorzolamide—CA9—Cellular responses to stress—TP53—urinary bladder cancer	0.000141	0.000873	CbGpPWpGaD
Dorzolamide—CA12—Metabolism—MTHFR—urinary bladder cancer	0.000139	0.00086	CbGpPWpGaD
Dorzolamide—CA4—Metabolism—GSTP1—urinary bladder cancer	0.000137	0.000844	CbGpPWpGaD
Dorzolamide—CA14—Metabolism—PPARG—urinary bladder cancer	0.000134	0.000827	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—NQO1—urinary bladder cancer	0.000132	0.000818	CbGpPWpGaD
Dorzolamide—CA2—Metabolism—GSTP1—urinary bladder cancer	0.000131	0.000809	CbGpPWpGaD
Dorzolamide—CA5A—Metabolism—PPARG—urinary bladder cancer	0.000131	0.000806	CbGpPWpGaD
Dorzolamide—CA6—Metabolism—PPARG—urinary bladder cancer	0.000131	0.000806	CbGpPWpGaD
Dorzolamide—CA14—Metabolism—CREBBP—urinary bladder cancer	0.000129	0.000794	CbGpPWpGaD
Dorzolamide—CA4—Metabolism—TYMS—urinary bladder cancer	0.000127	0.000785	CbGpPWpGaD
Dorzolamide—CA1—Metabolism—GSTP1—urinary bladder cancer	0.000126	0.000776	CbGpPWpGaD
Dorzolamide—CA4—Metabolism—NCOR1—urinary bladder cancer	0.000126	0.000776	CbGpPWpGaD
Dorzolamide—CA4—Metabolism—GSTM1—urinary bladder cancer	0.000126	0.000776	CbGpPWpGaD
Dorzolamide—CA6—Metabolism—CREBBP—urinary bladder cancer	0.000125	0.000774	CbGpPWpGaD
Dorzolamide—CA5A—Metabolism—CREBBP—urinary bladder cancer	0.000125	0.000774	CbGpPWpGaD
Dorzolamide—CA7—Metabolism—PPARG—urinary bladder cancer	0.000122	0.000752	CbGpPWpGaD
Dorzolamide—CA5B—Metabolism—PPARG—urinary bladder cancer	0.000122	0.000752	CbGpPWpGaD
Dorzolamide—CA2—Metabolism—TYMS—urinary bladder cancer	0.000122	0.000752	CbGpPWpGaD
Dorzolamide—CA2—Metabolism—GSTM1—urinary bladder cancer	0.00012	0.000744	CbGpPWpGaD
Dorzolamide—CA2—Metabolism—NCOR1—urinary bladder cancer	0.00012	0.000744	CbGpPWpGaD
Dorzolamide—CA4—Metabolism—GPX1—urinary bladder cancer	0.00012	0.000743	CbGpPWpGaD
Dorzolamide—CA4—Metabolism—ERCC2—urinary bladder cancer	0.000118	0.000729	CbGpPWpGaD
Dorzolamide—CA5B—Metabolism—CREBBP—urinary bladder cancer	0.000117	0.000723	CbGpPWpGaD
Dorzolamide—CA7—Metabolism—CREBBP—urinary bladder cancer	0.000117	0.000723	CbGpPWpGaD
Dorzolamide—CA1—Metabolism—TYMS—urinary bladder cancer	0.000117	0.000721	CbGpPWpGaD
Dorzolamide—CA1—Metabolism—NCOR1—urinary bladder cancer	0.000115	0.000713	CbGpPWpGaD
Dorzolamide—CA1—Metabolism—GSTM1—urinary bladder cancer	0.000115	0.000713	CbGpPWpGaD
Dorzolamide—CA2—Metabolism—GPX1—urinary bladder cancer	0.000115	0.000712	CbGpPWpGaD
Dorzolamide—CA2—Metabolism—ERCC2—urinary bladder cancer	0.000113	0.000699	CbGpPWpGaD
Dorzolamide—CA12—Metabolism—PPARG—urinary bladder cancer	0.000113	0.000697	CbGpPWpGaD
Dorzolamide—CA4—Metabolism—MTHFR—urinary bladder cancer	0.000111	0.000685	CbGpPWpGaD
Dorzolamide—CA1—Metabolism—GPX1—urinary bladder cancer	0.000111	0.000683	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—GSTP1—urinary bladder cancer	0.00011	0.000682	CbGpPWpGaD
Dorzolamide—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	0.000109	0.000671	CbGpPWpGaD
Dorzolamide—CA1—Metabolism—ERCC2—urinary bladder cancer	0.000109	0.00067	CbGpPWpGaD
Dorzolamide—CA12—Metabolism—CREBBP—urinary bladder cancer	0.000108	0.00067	CbGpPWpGaD
Dorzolamide—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000107	0.000662	CbGpPWpGaD
Dorzolamide—CA2—Metabolism—MTHFR—urinary bladder cancer	0.000106	0.000657	CbGpPWpGaD
Dorzolamide—CA14—Metabolism—PTGS2—urinary bladder cancer	0.000105	0.000651	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—TYMS—urinary bladder cancer	0.000103	0.000634	CbGpPWpGaD
Dorzolamide—CA5A—Metabolism—PTGS2—urinary bladder cancer	0.000103	0.000634	CbGpPWpGaD
Dorzolamide—CA6—Metabolism—PTGS2—urinary bladder cancer	0.000103	0.000634	CbGpPWpGaD
Dorzolamide—CA1—Metabolism—MTHFR—urinary bladder cancer	0.000102	0.00063	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—NCOR1—urinary bladder cancer	0.000101	0.000627	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—GSTM1—urinary bladder cancer	0.000101	0.000627	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	0.000101	0.000624	CbGpPWpGaD
Dorzolamide—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	9.99e-05	0.000617	CbGpPWpGaD
Dorzolamide—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	9.85e-05	0.000608	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—GPX1—urinary bladder cancer	9.72e-05	0.0006	CbGpPWpGaD
Dorzolamide—CA7—Metabolism—PTGS2—urinary bladder cancer	9.58e-05	0.000592	CbGpPWpGaD
Dorzolamide—CA5B—Metabolism—PTGS2—urinary bladder cancer	9.58e-05	0.000592	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	9.57e-05	0.000591	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—NAT1—urinary bladder cancer	9.57e-05	0.000591	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—ERCC2—urinary bladder cancer	9.54e-05	0.000589	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	9.42e-05	0.000581	CbGpPWpGaD
Dorzolamide—CA14—Metabolism—PTEN—urinary bladder cancer	9.19e-05	0.000567	CbGpPWpGaD
Dorzolamide—CA4—Metabolism—PPARG—urinary bladder cancer	9e-05	0.000556	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—MTHFR—urinary bladder cancer	8.97e-05	0.000554	CbGpPWpGaD
Dorzolamide—CA6—Metabolism—PTEN—urinary bladder cancer	8.95e-05	0.000553	CbGpPWpGaD
Dorzolamide—CA5A—Metabolism—PTEN—urinary bladder cancer	8.95e-05	0.000553	CbGpPWpGaD
Dorzolamide—CA12—Metabolism—PTGS2—urinary bladder cancer	8.88e-05	0.000548	CbGpPWpGaD
Dorzolamide—CA14—Metabolism—EP300—urinary bladder cancer	8.76e-05	0.000541	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	8.76e-05	0.000541	CbGpPWpGaD
Dorzolamide—CA4—Metabolism—CREBBP—urinary bladder cancer	8.65e-05	0.000534	CbGpPWpGaD
Dorzolamide—CA2—Metabolism—PPARG—urinary bladder cancer	8.63e-05	0.000533	CbGpPWpGaD
Dorzolamide—CA6—Metabolism—EP300—urinary bladder cancer	8.54e-05	0.000527	CbGpPWpGaD
Dorzolamide—CA5A—Metabolism—EP300—urinary bladder cancer	8.54e-05	0.000527	CbGpPWpGaD
Dorzolamide—CA5B—Metabolism—PTEN—urinary bladder cancer	8.36e-05	0.000516	CbGpPWpGaD
Dorzolamide—CA7—Metabolism—PTEN—urinary bladder cancer	8.36e-05	0.000516	CbGpPWpGaD
Dorzolamide—CA2—Metabolism—CREBBP—urinary bladder cancer	8.29e-05	0.000512	CbGpPWpGaD
Dorzolamide—CA1—Metabolism—PPARG—urinary bladder cancer	8.27e-05	0.000511	CbGpPWpGaD
Dorzolamide—CA7—Metabolism—EP300—urinary bladder cancer	7.97e-05	0.000492	CbGpPWpGaD
Dorzolamide—CA5B—Metabolism—EP300—urinary bladder cancer	7.97e-05	0.000492	CbGpPWpGaD
Dorzolamide—CA1—Metabolism—CREBBP—urinary bladder cancer	7.95e-05	0.000491	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	7.88e-05	0.000487	CbGpPWpGaD
Dorzolamide—CA12—Metabolism—PTEN—urinary bladder cancer	7.74e-05	0.000478	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	7.45e-05	0.00046	CbGpPWpGaD
Dorzolamide—CA12—Metabolism—EP300—urinary bladder cancer	7.39e-05	0.000456	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—PPARG—urinary bladder cancer	7.27e-05	0.000449	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	7.26e-05	0.000448	CbGpPWpGaD
Dorzolamide—CA4—Metabolism—PTGS2—urinary bladder cancer	7.08e-05	0.000437	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—CREBBP—urinary bladder cancer	6.99e-05	0.000431	CbGpPWpGaD
Dorzolamide—CA2—Metabolism—PTGS2—urinary bladder cancer	6.79e-05	0.000419	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	6.66e-05	0.000411	CbGpPWpGaD
Dorzolamide—CA1—Metabolism—PTGS2—urinary bladder cancer	6.51e-05	0.000402	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	6.31e-05	0.00039	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—NAT1—urinary bladder cancer	6.31e-05	0.00039	CbGpPWpGaD
Dorzolamide—CA4—Metabolism—PTEN—urinary bladder cancer	6.18e-05	0.000381	CbGpPWpGaD
Dorzolamide—CA2—Metabolism—PTEN—urinary bladder cancer	5.92e-05	0.000366	CbGpPWpGaD
Dorzolamide—CA4—Metabolism—EP300—urinary bladder cancer	5.89e-05	0.000364	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	5.82e-05	0.000359	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—TYMP—urinary bladder cancer	5.8e-05	0.000358	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	5.77e-05	0.000357	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—PTGS2—urinary bladder cancer	5.72e-05	0.000353	CbGpPWpGaD
Dorzolamide—CA1—Metabolism—PTEN—urinary bladder cancer	5.68e-05	0.00035	CbGpPWpGaD
Dorzolamide—CA2—Metabolism—EP300—urinary bladder cancer	5.65e-05	0.000349	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	5.57e-05	0.000344	CbGpPWpGaD
Dorzolamide—CA1—Metabolism—EP300—urinary bladder cancer	5.41e-05	0.000334	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—NAT2—urinary bladder cancer	5.25e-05	0.000324	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	5.2e-05	0.000321	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—PTEN—urinary bladder cancer	4.99e-05	0.000308	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	4.91e-05	0.000303	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	4.79e-05	0.000295	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—EP300—urinary bladder cancer	4.76e-05	0.000294	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—RRM2—urinary bladder cancer	4.53e-05	0.00028	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	4.19e-05	0.000259	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—ENO2—urinary bladder cancer	4.19e-05	0.000259	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.17e-05	0.000257	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	4.07e-05	0.000251	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.01e-05	0.000247	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—TYMP—urinary bladder cancer	3.83e-05	0.000236	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—NAT2—urinary bladder cancer	3.46e-05	0.000214	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—NQO1—urinary bladder cancer	3.38e-05	0.000209	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.28e-05	0.000203	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—RRM2—urinary bladder cancer	2.99e-05	0.000184	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.86e-05	0.000177	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	2.82e-05	0.000174	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	2.77e-05	0.000171	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—ENO2—urinary bladder cancer	2.77e-05	0.000171	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.73e-05	0.000168	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	2.68e-05	0.000166	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—TYMS—urinary bladder cancer	2.62e-05	0.000162	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	2.59e-05	0.00016	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	2.59e-05	0.00016	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—GPX1—urinary bladder cancer	2.48e-05	0.000153	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	2.44e-05	0.00015	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	2.29e-05	0.000141	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—NQO1—urinary bladder cancer	2.23e-05	0.000138	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.86e-05	0.000115	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—PPARG—urinary bladder cancer	1.86e-05	0.000115	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	1.78e-05	0.00011	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.73e-05	0.000107	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.71e-05	0.000106	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.71e-05	0.000106	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.64e-05	0.000101	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.61e-05	9.92e-05	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.51e-05	9.32e-05	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	1.46e-05	9.02e-05	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—PTEN—urinary bladder cancer	1.27e-05	7.87e-05	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.22e-05	7.56e-05	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—EP300—urinary bladder cancer	1.21e-05	7.5e-05	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.18e-05	7.26e-05	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	9.63e-06	5.95e-05	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—PTEN—urinary bladder cancer	8.4e-06	5.19e-05	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—EP300—urinary bladder cancer	8.01e-06	4.95e-05	CbGpPWpGaD
